# Study Evaluating of Calcineurin Inhibitor and Sirolimus (Rapamune) Treatment in Liver Transplant Recipients

> **NCT00086346** · PHASE3 · TERMINATED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 607 (actual)

## Conditions studied

- Liver Transplantation

## Interventions

- **DRUG:** Sirolimus (Rapamune)
- **DRUG:** Cyclosporine or Tacrolimus

## Key facts

- **NCT ID:** NCT00086346
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2002-12
- **Primary completion:** 2008-07
- **Final completion:** 2008-07
- **Target enrollment:** 607 (ACTUAL)
- **Last updated:** 2010-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00086346

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00086346, "Study Evaluating of Calcineurin Inhibitor and Sirolimus (Rapamune) Treatment in Liver Transplant Recipients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00086346. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*